Paper36980678
NKG2D Fine-Tunes the Local Inflammatory Response in Colorectal Cancer.
Curio S and 8 others. Cancers (Basel), 2023. Cited by 8 papers, by iCite.
Cite this record
ConductScience Library. NKG2D Fine-Tunes the Local Inflammatory Response in Colorectal Cancer. Papers, record 36980678. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36980678
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants4
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| Wellcome Trust | United Kingdom | PubMed | ||
| 22255 | Cancer Research UK | United Kingdom | PubMed | |
| 203948/Z/16A | Wellcome Trust | United Kingdom | PubMed | |
| RCDF088381/Z/09/Z | Wellcome Trust | United Kingdom | PubMed |
Source PubMed
References44
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 28366766 | Phase I Escalating-Dose Trial of CAR-T Therapy Targeting CEA+ Metastatic Colorectal Cancers. | Mol Ther | 2017 | https://conductscience.org/library/papers/28366766 | PubMed |
| 2 | 33613769 | CAR-T cells for Colorectal Cancer: Target-selection and strategies for improved activity and safety. | J Cancer | 2021 | https://conductscience.org/library/papers/33613769 | PubMed |
| 3 | 16184547 | Expression of the stress-related MHC class I chain-related protein MICA is an indicator of good prognosis in colorectal cancer patients. | Int J Cancer | 2006 | https://conductscience.org/library/papers/16184547 | PubMed |
| 4 | 34719204 | Expression of MHC class I polypeptide-related sequence A (MICA) in colorectal cancer. | Front Biosci (Landmark Ed) | 2021 | https://conductscience.org/library/papers/34719204 | PubMed |
| 5 | 7576992 | ApcMin: a mouse model for intestinal and mammary tumorigenesis. | Eur J Cancer | 1995 | https://conductscience.org/library/papers/7576992 | PubMed |
| 6 | 33868281 | Major Histocompatibility Complex Class I-Related Chain A (MICA) Allelic Variants Associate With Susceptibility and Prognosis of Gastric Cancer. | Front Immunol | 2021 | https://conductscience.org/library/papers/33868281 | PubMed |
| 7 | 29786848 | Annual Report to the Nation on the Status of Cancer, part I: National cancer statistics. | Cancer | 2018 | https://conductscience.org/library/papers/29786848 | PubMed |
| 8 | 27912061 | Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade. | Cell | 2016 | https://conductscience.org/library/papers/27912061 | PubMed |
| 9 | 35191428 | Clinical Grade Manufacture of CYAD-101, a NKG2D-based, First in Class, Non-Gene-edited Allogeneic CAR T-Cell Therapy. | J Immunother | 2022 | https://conductscience.org/library/papers/35191428 | PubMed |
| 10 | 36764323 | CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial. | Lancet Haematol | 2023 | https://conductscience.org/library/papers/36764323 | PubMed |
| 11 | 28344808 | Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer. | J Immunother Cancer | 2017 | https://conductscience.org/library/papers/28344808 | PubMed |
| 12 | 32853984 | CAR-NK cells: A promising cellular immunotherapy for cancer. | EBioMedicine | 2020 | https://conductscience.org/library/papers/32853984 | PubMed |
| 13 | 30984204 | NKG2D/NKG2-Ligand Pathway Offers New Opportunities in Cancer Treatment. | Front Immunol | 2019 | https://conductscience.org/library/papers/30984204 | PubMed |
| 14 | 26041808 | NKG2D Receptor and Its Ligands in Host Defense. | Cancer Immunol Res | 2015 | https://conductscience.org/library/papers/26041808 | PubMed |
| 15 | 33142138 | Expression of NK cell receptor ligands in primary colorectal cancer tissue in relation to the phenotype of circulating NK- and NKT cells, and clinical outcome. | Mol Immunol | 2020 | https://conductscience.org/library/papers/33142138 | PubMed |
| 16 | 14762782 | Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. | Gastroenterology | 2004 | https://conductscience.org/library/papers/14762782 | PubMed |
| 17 | 17052257 | Multistep carcinogenesis of the colon in Apc(Min/+) mouse. | Cancer Sci | 2007 | https://conductscience.org/library/papers/17052257 | PubMed |
| 18 | 26442803 | Strain-dependent Lethal Toxicity in NKG2D Ligand-targeted CAR T-cell Therapy. | Mol Ther | 2015 | https://conductscience.org/library/papers/26442803 | PubMed |
| 19 | 27849169 | Mechanisms of Acute Toxicity in NKG2D Chimeric Antigen Receptor T Cell-Treated Mice. | J Immunol | 2016 | https://conductscience.org/library/papers/27849169 | PubMed |
| 20 | 26457759 | The consensus molecular subtypes of colorectal cancer. | Nat Med | 2015 | https://conductscience.org/library/papers/26457759 | PubMed |
Cited by6
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 8 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 40868987 | Molecular Mechanisms of Phytochemicals from Chaga Mushroom (Inonotus obliquus) Against Colorectal Cancer: Insights from Network Pharmacology, Molecular Docking, and Bioinformatics. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/40868987 | PubMed |
| 40849493 | Unleashing NK cells for cancer immunotherapy in lung cancer: biologic challenges and clinical advances. | J Exp Clin Cancer Res | 2025 | https://conductscience.org/library/papers/40849493 | PubMed |
| 40534857 | T cell-mediated immune surveillance conferred by latent Epstein-Barr virus genes suppresses a broad spectrum of tumor formation through NKG2D-NKG2DL interactions. | Front Immunol | 2025 | https://conductscience.org/library/papers/40534857 | PubMed |
| 39817244 | Cell type-specific upregulation of NKG2D ligand MICA in response to APTO253. | Ann Transl Med | 2024 | https://conductscience.org/library/papers/39817244 | PubMed |
| 38948479 | Navigating through novelties concerning mCRC treatment-the role of immunotherapy, chemotherapy, and targeted therapy in mCRC. | Front Surg | 2024 | https://conductscience.org/library/papers/38948479 | PubMed |
| 37626965 | The Role and Regulation of the NKG2D/NKG2D Ligand System in Cancer. | Biology (Basel) | 2023 | https://conductscience.org/library/papers/37626965 | PubMed |
Genes26
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36980678
GET https://conductscience.org/api/papers/v1/36980678/references?page=2